Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide.

Abstract

Pulmonary MALT lymphoma is a rare disease entity and generally follows an indolent clinical course. Due to scarce information from randomized prospective trials, no standardized therapy protocols exist. Besides irradiation and chemotherapy, novel biological agents such as the anti CD20-antibody rituximab and thalidomide constitute a promising new approach. In this report we demonstrate the case of a 52-year-old male patient with extra-intestinal MALT lymphoma of the lung. After 10 months of treatment with low dose thalidomide (100mg/d), very good partial response of the intrapulmonary lesions was achieved.

• Authors: Mathias Kees, Markus Raderer, Sylvia Metz-Schimmerl, Andreas Chott, Heinz Gisslinger
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 46 Issue 9 Pg. 1379-82 (Sep 2005) ISSN: 1042-8194 [Print] United States
• PMID: 16109619 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Thalidomide

Topics

• Humans
• Lung Neoplasms (diagnostic imaging, drug therapy)
• Lymphoma, B-Cell, Marginal Zone (diagnostic imaging, drug therapy)
• Male
• Middle Aged
• Thalidomide (therapeutic use)
• Tomography, X-Ray Computed